Company Overview and News

 
Leverage data to go further

2018-10-08 thestar.com.my
Data driven: (from left) Moderator MAICCI secretary-general Datuk Dr A T Kumararajah discusses the use of data with Ng, Meehan and Teh.
6084 0181

 
Leverage data to go further

2018-10-07 thestar.com.my
Data driven: (from left) Moderator MAICCI secretary-general Datuk Dr A T Kumararajah discusses the use of data with Ng, Meehan and Teh.
6084 0181

 
Ride upside of technology

2018-09-30 thestar.com.my
APPS, smart systems, automation – these are only the beginning of what industry captains say may be an eventful journey towards having a business that is digitally supported and enabled.
6084 0181

 
Stock With Momentum: Aemulus Holdings

2018-07-19 theedgemarkets
TRADING in Aemulus Holdings Bhd (fundamental: 2.25/3, valuation: 0.8/3) shares triggered our proprietary momentum algorithm yesterday for the third time this year.
0181

 
Aemulus may trend higher, says RHB Retail Research

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): RHB Retail Research said Aemulus Holdings Bhd may trend higher after it formed a long white candle and breached above the 40 sen threshold.
0181

9
Choosing between JF Technology and FoundPac

2018-06-13 theedgemarkets
INVESTORS in semiconductor and semiconductor-related companies listed on Bursa Malaysia were laughing all the way to the bank following a surge in share prices last year. The likes of Unisem (M) Bhd, Globetronics Technology Bhd, Inari Amertron Bhd and Malaysian Pacific Industries Bhd (MPI), as well as ViTrox Corp Bhd, Elsoft Research Bhd, Aemulus Holdings Bhd and MMS Ventures Bhd climbed at least 50% to as much as 290% in 2017.
0166 0146 0113 3867 0090 0181 BSMAF 7022 GBTKF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...